SOURCE: AgraQuest


October 31, 2011 04:00 ET

Bayer and AgraQuest Expand Distribution Agreement for Asia/Pacific and South America Regarding Poultry Nutrition Supplement

Agreement Will Allow Bayer to Distribute Patented AgraQuest Technology Into Poultry Markets

MONHEIM, GERMANY--(Marketwire - Oct 31, 2011) - Bayer Animal Health GmbH and AgraQuest, Inc. announced today that they have agreed to expand their collaboration and will allow Bayer to become the exclusive distributor of AgraQuest's Bacillus subtilis QST 713 in selected countries for poultry applications.

The product that will be distributed under the agreement will be Baymix® Grobig® BS, a feed additive based on AgraQuest's patented strain of Bacillus subtilis and co-branded with AgraQuest's trademark SYMPATIC™. Baymix® Grobig® BS has already received registration in India, Korea and Thailand and is already marketed by Bayer Animal Health in these countries. It will be launched in other key markets throughout Asia and Latin America, with registrations currently in process in eight countries.

"Bayer is looking forward to a long-term relationship with AgraQuest which will contribute to further foster our target to complete our customers' needs," says Alexander Jahn, Head of Region Asia within Bayer HealthCare Animal Health. "We already started to partner successfully in selected countries like India for example, which is one of the fastest growing poultry markets in Asia. With our excellent distribution footprint across most of the growing markets, we will contribute to a continuous success of Baymix®Grobig®, especially in those markets, where the importance of poultry is increasing."

"We are excited to expand our relationship with a company that is both technically astute and so well experienced in the animal health market," said Mike Miille, President and COO of AgraQuest. "By combining strengths of both Bayer and AgraQuest, we can deliver cost effective and consistently performing natural products to poultry producers."

Baymix® Grobig® BS is a product designed to be complementary to existing poultry health regimes, brings balance to microflora of the intestinal tract of poultry. The genetically distinct QST 713 strain enhances digestion and has been shown to protect birds from profit robbing diseases such as necrotic enteritis.

"By teaming with Bayer in these key poultry markets, we can deliver to producers a product that allows treated poultry to reach their full genetic potential and maximize their return on investment," said Joe Schmidt, Vice President at AgraQuest. "We look forward to working with the Bayer country teams on this exciting offering."

About AgraQuest
AgraQuest is a global biotechnology company that focuses on discovering, manufacturing and marketing highly effective pest and disease management products to increase agricultural production efficiencies. As a leader in green agriculture and the emerging low chem sector, AgraQuest is at the forefront of changes in food production by providing growers and producers with solutions that offer best-in-class management while reducing the chemical load on the environment and creating sustainable agriculture opportunities. Through its Agrochemical and BioInnovations divisions, AgraQuest focuses on natural products designed for pest and disease control and yield improvements for global crop and animal agriculture, the garden, and in food safety markets. For more information on the role AgraQuest innovations will play in Better Food and a Better World, visit

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at

With a turnover of EUR 1.120 million (2010) Bayer HealthCare's Animal Health Division is one of the world's leading manufacturers of veterinary drugs. The division manufactures and markets more than 100 different veterinary drugs and care products for livestock and companion animals.

Find more information at

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.